MN-001

DRUG4 trials

Sponsors

MediciNova

Conditions

Diabetes Mellitus, Type 2HypercholesterolemiaHypertriglyceridemiaIPFIdiopathic Pulmonary FibrosisInterstitial CystitisNon-Alcoholic Fatty Liver DiseaseNon-alcoholic Fatty Liver Disease

Phase 2

Phase II Study Efficacy and Safety of Two Dosing Regimens of MN-001 in Patients With Interstitial Cystitis

CompletedNCT00295854

MediciNovaInterstitial Cystitis

Start: 2005-05-31End: 2006-10-31Updated: 2012-01-19

Safety, Tolerability, and Efficacy of MN-001 (Tipelukast) in Patients With Idiopathic Pulmonary Fibrosis

CompletedNCT02503657

MediciNovaIdiopathic Pulmonary Fibrosis, IPF

Start: 2016-03-09End: 2022-03-15Updated: 2026-01-23

Open-Label Study To Evaluate MN-001 on HDL & Triglyceride in NASH & NAFLD Subjects

CompletedNCT02681055

MediciNovaHypercholesterolemia, Hypertriglyceridemia, Non-alcoholic Fatty Liver Disease +1

Start: 2016-03-31End: 2019-10-01Updated: 2023-03-15

MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia

Active, not recruitingNCT05464784

MediciNovaDiabetes Mellitus, Type 2, Hypertriglyceridemia, Non-Alcoholic Fatty Liver Disease

Start: 2022-08-22End: 2026-12-31Target: 40Updated: 2026-02-05